Generic Vivactil Availability
Last updated on Sep 10, 2026.
Vivactil is a brand name of protriptyline, approved by the FDA in the following formulation:
| Manufacturer | Approval date | Strengths [AB] |
|---|---|---|
| TEVA WOMENS | Approved Prior to Jan 1, 1982 |
|
All of the above formulations have been discontinued.
Has a generic version of Vivactil been approved?
Yes, the FDA has approved a generic version of Vivactil. However, FDA approval doesn't guarantee the generic will be available in pharmacies.
| Manufacturer | Approval date | Strengths [AB] |
|---|---|---|
| SIGMAPHARM LABS LLC | May 3, 2010 |
|
| EPIC PHARMA LLC | November 19, 2012 |
|
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vivactil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Generic Vivactil prices
The pricing data below reflects current availability in the marketplace and indicates that the medication is available for purchase.
| Drug | Form | Strength | Drugs.com Price Guide |
|---|---|---|---|
| Protriptyline Hydrochloride | oral tablet | 5 mg | from $48.86 for 30 |
| Protriptyline Hydrochloride | oral tablet | 10 mg | from $49.99 for 30 |
|
See all prices for: Protriptyline Hydrochloride |
|||
Generic Vivactil images
Images of protriptyline (generic Vivactil). See all images
E 7
- Sigmapharm Laboratories, LLC
- Strength
- 10 mg
- Imprint
- E 7
- Color
- Yellow
- Shape
- Round
E 4
- Sigmapharm Laboratories, LLC
- Strength
- 5 mg
- Imprint
- E 4
- Color
- Orange
- Shape
- Round
E96
- Epic Pharma, LLC
- Strength
- 5 mg
- Imprint
- E96
- Color
- Orange
- Shape
- Round
Generic Vivactil Marketing Start Dates
Marketing start dates are when each generic version first became available from each manufacturer.
Discontinued generic versions of Vivactil
The following generic formulations of Vivactil have been discontinued:
| Manufacturer | Approval date | Strengths [AB] |
|---|---|---|
| CHARTWELL RX | August 24, 1995 |
|
More about Vivactil (protriptyline)
- Check interactions
- Compare alternatives
- Reviews (4)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: tricyclic antidepressants
- Breastfeeding
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| AB | Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.